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Abstract
Estrogen receptor a (ERa) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast
cancers, however, are hormone- independent because of lack of ERa expression. New strategies are needed for re-
expression of ERa and sensitization of ER-negative breast cancer cells to selective ER modulators. The present report shows
that arsenic trioxide induces reactivated ERa, providing a target for therapy with ER antagonists. Exposure of ER-negative
breast cancer cells to arsenic trioxide leads to re-expression of ERa mRNA and functional ERa protein in in vitro and in vivo.
Luciferase reporter gene assays and 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)- 2H-
tetrazolium (MTS) assays show that, upon exposure to arsenic trioxide, formerly unresponsive, ER-negative MDA-MB-231
breast cancer cells become responsive to ER antagonists, 4-hydroxytamoxifen and ICI 182,780. Furthermore, methylation-
specific PCR and bisulfite-sequencing PCR assays show that arsenic trioxide induces partial demethylation of the ERa
promoter. A methyl donor, S-adenosylmethionine (SAM), reduces the degree of arsenic trioxide-induced re-expression of
ERa and demethylation. Moreover, Western blot and ChIP assays show that arsenic trioxide represses expression of DNMT1
and DNMT3a along with partial dissociation of DNMT1 from the ERa promoter. Thus, arsenic trioxide exhibits a previously
undefined function which induces re-expression ERa in ER-negative breast cancer cells through demethylation of the ERa
promoter. These findings could provide important information regarding the application of therapeutic agents targeting
epigenetic changes in breast cancers and potential implication of arsenic trioxide as a new drug for the treatment of ER–
negative human breast cancer.
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Introduction
Breast cancer is the most common tumor in women, and it is the
cause of considerable morbidity and mortality. The tumor
expression of estrogen receptors (ERs) is a marker for prognosis
and is predictive of response to endocrine therapy [1]. Approx-
imately two-thirds of breast cancers express ER gene and
synthesize ER protein. These tumors tend to be more differen-
tiated and are often responsive to hormonal therapies. One-third
of breast cancers, however, lack ER. Loss of ER expression is
generally associated with poor histological differentiation, high
growth fractions, and inferior clinical outcomes [2]. These cancers,
which are apparently estrogen-independent, rarely respond to
hormonal therapies. In addition, some breast cancers that are
initially ER-positive lose ER expression during tumor progression
[3].
To date, the molecular mechanisms underlying the loss of ERs
in breast cancer are poorly understood. Deletions, insertions,
rearrangements, or polymorphisms of ER genes are infrequent
and are not generally associated with loss of ER [4]. It has been
shown that breast cancer, similar to other types of cancer, is also a
disease that is driven by epigenetic alterations, which do not affect
the primary DNA sequence [5,6]. Epigenetic alterations include
DNA methylation, histone modifications and so on. In human
breast carcinomas, an abnormal methylation pattern could
account for transcriptional inactivation of the ER gene and
subsequent hormone resistance. Loss of ER is premodinantly a
result of hypermethylation of CpG islands, cytosine–guanine-rich
areas that are located in the 59 regulatory regions of the ER gene
[2,7,8]. Theoretically, if the elimination of ERa expression is a
consequence of hypermethylation of these islands, this effect could
be reversed by a DNA demethylating agent. Other epigenetic
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involved in the complex mechanisms that regulate promoter
transcription. Demethylating agents and histone deacetylase
(HDAC) inhibitors, which are candidates for new cancer
therapeutics, can produce a synergistic reactivation to restore
ERa protein expression in ER–negative breast cancer cells [3].
Arsenic trioxide, which has been used clinically as an anti-tumor
agent, induces demethylation and apoptosis [9], while little is
known regarding the mechanism of its anti-tumor effect.
Intracellular arsenic metabolism and DNA methylation require
S-adenosylmethionine (SAM) as a methyl donor, and the
consumption of methyl groups in arsenic biotransformation
presumably results in a deficiency of methyl donors, reducing
DNA methylation [10]. Thus, arsenic trioxide possibly induces
demethylation and re-expression of certain genes. To date,
however, whether arsenic trioxide can re-express ERa in ER-
negative breast cancer cells has not been investigated. In the
present study, ER–negative human breast cancer cells were
exposed to arsenic trioxide to test the hypothesis that ERa
promoter hypermethylation could be reversed, leading to
reactivation of the ERa gene. We thought that data from our
study could provide important information regarding the potential
implication of arsenic trioxide as a new drug for treatment of ER–
negative human breast cancer.
Materials and Methods
Chemicals, reagents, and supplies
Arsenic trioxide, b-estradiol (E2), 4-hydroxytamoxifen (OH-
T),ICI 182,780 (ICI) and 5-aza-29-deoxycytidine (AZA) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA). SAM
was from New England BioLabs. TRIzol reagent, L-15 medium,
Dulbecco’s modified Eagle’s medium (DMEM), and trypsin were
from Gibco/Invitrogen (Carlsbad, CA, USA). DNeasy Blood &
Tissue kits were obtained from QIAGEN (Alameda, CA, USA).
CpGenome DNA modification kits and Magna ChIP
TM G One-
Day Chromatin Immunoprecipitation Kits were purchased from
Millipore (Billerica, MA, USA). Fetal bovine serum (FBS) was
obtained from PAA Laboratories (Pasching, Austria) and charcoal-
stripped FBS (CS-FBS) from Biological Industries (Kibbutz Beit
Haemek, Israel).
Rabbit polyclonal antibodies against ERa, b-actin, and
GAPDH were obtained from NeoMarkers (Fremont, CA, USA),
and the mouse monoclonal antibodies against DNMT1,DNMT3a
and DNMT3b was obtained from Abnova (Taipei, Taiwan). Anti-
rabbit and anti-mouse peroxidase-conjugated antibodies were
obtained from Upstate Biotechnology (Charlottesville, VA, USA).
Sheep polyclonal antibodies against MBD2 were obtained from
Millipore (Billerica, MA, USA). The pEASY-T3 Cloning Kit was
from Beijing TransGen Biotech Co. (Beijing, China). Enhanced
chemiluminescence detection reagents were obtained from
Amersham Biosciences (Piscataway, NJ, USA). The tetrazolium
compound, 3-(4,5-dimethylthiazol-2-yl)-5– (3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and lysis buffer
were obtained from Promega Biotech Co. (Beijing, China). The
Sofast
TM transfection reagent was purchased from Sunma Co.
(Xiamen, China). Methyl Primer Express software was purchased
from Applied Biosystems (Foster City, CA, USA).
Plasmids
The luciferase reporter plasmid pERE-TATA-Luc+ and rat
ERa expression vector rERa/pCI were provided by Dr. M.
Takeyoshi (Chemicals Assessment Center, Chemicals Evaluation
and Research Institute, Oita, Japan). The plasmids were
constructed as previously described [11]. The plasmid phRL-tk
containing the Renilla luciferase gene (used as an internal control
for transfection efficiency and cytotoxicity of test chemicals) and
the Dual-Luciferase Reporter Assay System Kit were purchased
from Promega (Madison, WI, USA).
Cell culture and treatments
Human breast cancer cells, MDA-MB-231, Hs578T and MCF-
7, were obtained from American Type Culture Collection
(Rockville, MD, USA), and were maintained according to ATCC’s
recommendation. MDA-MB-231 cells were maintained in L-15
medium; MCF-7 and Hs578T cells were routinely maintained in
DMEM. Both media were supplemented with 100 IU/mL
penicillin, 100 mg/mL streptomycin, and 10% FBS. MCF-7 and
Hs 578T cells were incubated at 37uCi n5 %C O 2; MDA-MB-231
cells were grown in the absence of CO2. Cells were seeded at a
density of 2610
5 per 100-mm tissue culture dish in phenol red–
free DMEM supplemented with 10% CS-FBS (estrogen-free), and
the medium was changed every other day for 6 days. After 24 hr,
the estrogen-free medium was changed to estrogen-free medium
containing 1, 2, or 4 mmol/L of arsenic trioxide or 200 mmol/L of
SAM for 6 days. Cells untreated or pretreated with arsenic
trioxide/SAM were exposed to E2 (100 nmol/L for 24 hr), OHT
(10 mmol/L for 24 hr), ICI (2 mmol/L for 24 hr), or to the vehicle
in fresh estrogen-free medium for indicated time periods. The
media, with or without added compounds, were renewed every
second day. For cell proliferation assays, reverse transcription
polymerase chain reactions (RT-PCR), and reporter gene analysis,
cells were switched to phenol red-free MEM (without E2)
supplemented with 5% CS-FBS at least 5 days before exposure
E2, OHT, or ICI. The experiments were repeated twice, and each
cell line was tested in triplicate.
Cell growth assay
MDA-MB-231 cells were plated at a density of 4610
3 cells/well
into 96-well plates and cultured with phenol red-free MEM
supplemented with 5% CS-FBS. After 24 hr, the medium was
replaced, and the cells were exposed to arsenic trioxide for 6 days.
Cells untreated or pretreated with arsenic trioxide were exposed to
E2, OHT, ICI, or vehicle in fresh estrogen-free medium for
indicated time periods. At appropriate times, MTS was added to
each well, and the plates were further incubated for 4 hr at 37uC.
The absorbance at 490 nm was measured with a Multiscan MCC
340 microplate reader (Titertek, Huntsville, AL, USA). All
measurements were performed in triplicate. Data points repre-
sented the means of the values for the four wells. Cellular
proliferation was expressed as the mean numbers of cells 6 SEM.
Nude mice xenograft model
Female nude mice (6 weeks old; BALB/cA-nu (nu/nu)) were
purchased from Shanghai Laboratory Animal Center (SLAC,
Shanghai, China) and maintained in pathogen-free conditions.
The use and care of animals in this study is approved by the
Institutional Animal Care and Use Committee of Nanjing Medical
University (Approval ID 20100234). MDA-MB-231 cells (1610
7
cells) were injected into both flanks of each nude mouse, and
tumors were allowed to grow for 6 weeks. Ten mice were
randomly divided into 2 groups. For arsenic trioxide-treated
group, 2 mg/kg.bw arsenic trioxide (The dose was selected based
on the commonly used clinical dose of 10 mg/d which was
converted to the dose in nude mice) was administered i.p. in
100 ml of sterile saline every other day. For control group, the
nude mice were treated with the same volume of PBS. Mice were
sacrificed after 4 weeks of treatments. Tumors were removed from
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nitrogen. Tumors were also fixed with 10% formalin solution for
immunohistochemical staining.
RNA isolation and RT-PCR
Cells were grown in 6-cm plastic dishes (1610
6 cells/dish in
5 mL of estrogen-free medium). At 24 hr after plating, the test
compounds were added. Total cellular RNA was extracted by use
of the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
quantified by UV absorption. From each sample, 1 mg was
reverse-transcribed by M-MLV first-stand amplification of ERa,
pS2 and GREB1 (estrogen-responsive genes), and the constitu-
tively expressed housekeeping gene, GAPDH. Primers for ERa
were 59-CCACCAACCAGTGCACCATT-39 (forward) and 59-
GTCTTTCCG TATCCCACCTTTC-39 (reverse). Primers for
pS2 and GREB1 and the PCR conditions have been described
previously [12]. The PCR products were resolved by 2% agarose
gel electrophoresis and detected by UV transillumination after
staining with ethidium bromide.
Western blot analyses
The cells were washed twice with ice-cold PBS, scraped into
0.2 mL of buffer [20 mM HEPES (pH 6.8), 5 mM EDTA,
10 mM EGTA, 5 mM NaF, 0.1 mg/mL okadaic acid, 1 mM
dithiothreitol, 0.4 M KCl, 0.4% Triton X-100, 10% glycerol,
5 mg/mL leupeptin, 50 mg/mL of phenylmethanesulphonylfluor-
ide, 1 mM benzamidine, 5 mg/mL aprotinin and 1 mM sodium
orthovanadate], and incubated on ice for 30 min, followed by
centrifugation at 12,000 rpm for 15 min. The supernatant was
stored at 270uC. Protein concentrations were measured with the
BCA Protein Assay (Pierce, Rockford, IL, USA). Afterwards,
proteins were diluted to equal concentrations, boiled for 5 min,
and separated by 7%–12% sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis. Proteins were transferred to nitrocellu-
lose membranes, which were probed with ERa and DNMT1
antibodies overnight at 4uC. Membranes were incubated with
horseradish peroxidase-conjugated secondary antibodies for 1 hr
at room temperature to enhance chemiluminescence (Amersham
Biosciences, Piscataway, NJ, USA) before exposure to film.
GAPDH or b-actin was used to normalize for protein loading.
All experiments were performed at least twice; similar results were
obtained.
Transfection and luciferase reporter gene assays
MDA-MB-231 cells were placed in 24-well microplates at a
density of 5.0610
3 cells/well in the phenol-red-free MEM
containing 5% CS-FBS. Following 24 hr of incubation, the cells
were exposed to arsenic trioxide for 6 days, then transfected with
0.5 mg of pERE-TATA-Luc+, 0.2 mg of rERa/pCI, and 0.1 mgo f
phRL-tk, with 5 mg of Sofast
TM transfection reagent per well.
After incubation for 12 hr, the transfection medium was replaced.
After being exposed to the test chemicals for 24 hr, the cells were
harvested. Following three rinses with PBS (pH 7.4), the cells were
lysed with 16passive lysis buffer. The cell lysates were analyzed
immediately with a 96-well plate luminometer. The amounts of
luciferase and Renilla luciferase were measured with the Dual-
Luciferase Reporter Assay System Kit following the manufactur-
er’s instructions. The value of luciferase activity for each lysate was
normalized to the Renilla luciferase activity. The relative
transcriptional activity was converted into fold induction above
the vehicle control value (n-fold).
Bisulfite sequencing PCR (BSP)
Genomic DNA was isolated by use of a DNeasy Blood & Tissue
kit. Isolated DNA was subjected to modification by use of a
CpGenome DNA modification kit according to the manufacturer’s
recommendations and amplified via PCR with primers for the
ERa promoter region. From the bisulfite-modified DNA, the ERa
promoter was amplified by PCR under conditions described
previously [12]. ERS primers were 59-TGTTTGGAGT-
GATGTTTAAGTT-39 and 59- CAATAAAACCATCCCAAA-
TACT-39. PCR products were gel purified and cloned using the
pEASY-T3 Cloning Kit (Beijing TransGen Biotech Co., Ltd.).
Ten random clones were sequenced by the Invitrogen Company.
Methylation-specific PCR (MSP) analysis
The ER gene promoter was amplified from bisulfite-modified
DNA by two rounds of PCR using nested primers specific to the
bisulfite-modified sequence of the CpG island of the ER gene. The
first-round PCR involved BSP primers; the second-round primers
specifically recognized the unmethylated or methylated promoter
sequences after bisulfite conversion. ER unmethylated primers
were 59-TTTTGGGATTGTATTTGTTTTTGTTG-39 and 59-
AAACAAAATACAAACCATATCCCCA-39; ER methylated
primers were 59-TTTTGGGATTGTATTTGTTTTCGTC-39
and 59-AACAAAATACAAACCGTATCCCCG-39. Both rounds
of PCR were performed under the same conditions, with 2 mLo fa
50-fold dilution of the first-round PCR product serving as the
template for the second-round MSP. Amplification was performed
under the conditions described above. PCR products were
subjected to electrophoresis on 2% agarose gels.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was performed
using the Magna ChIP Assay Kit(Millipore) according to the
manufacturer’s instructions. DNA cross-linking was performed by
adding 1% formaldehyde into cell cultures at room temperature
for 10 min, and glycine was then added (0.125 M final
concentration) for 5 min to stop the cross-linking reaction. Cells
were lysed with a lysis buffer with protease inhibitors and sonicated
to shear genomic DNA to lengths between 200 and 800 bp. One-
tenth of the cell lysate was used for input control and the rest was
used for immunoprecipitation using antibodies against DNMT1.
After collecting immunoprecipitates using protein G agarose
columns, protein–DNA complexes were eluted and heated at 62
to reverse the cross-linking. After digestion with proteinase K,
DNA fragments were purified by spin columns and analyzed by
PCR. The ER promoter was analyzed using the 59-primer 59-
AGTTGTGCCTGGAGTGATG-39 and the 39-primer 59-GCA-
GAAGGCTCAGAAACC-39. Initially, PCR was performed with
different numbers of cycles or dilutions of input DNA to determine
the linear range of the amplification; all results shown fall within
this range. After 30 cycles of amplification, PCR products were
run on 2% agarose gel and analyzed by ethidium bromide
staining. All ChIP assays were performed at least twice with similar
results.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded tumor samples. Sections mounted on
silanized slides were dewaxed in xylene, dehydrated in ethanol,
boiled in 0.01 M citrate buffer (pH 6.0) for 20 min in a microwave
oven and then incubated with 3% hydrogen peroxide for 5 min.
After washing with PBS, sections were incubated in 10% normal
BSA for 5 min, followed by overnight incubation with rabbit anti-
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horseradish peroxidase–conjugated secondary antibody at room
temperature for 30 minutes. The sections were then counter-
stained with hematoxylin, dehydrated, cleared, and mounted.
Statistical analyses
The data were recorded as means 6 SD. Statistical comparisons
between control and treated groups were performed using either
Student’s t test or single-factor ANOVA model. p,0.05 was
considered to indicate a statistically significant difference.
Results
Arsenic trioxide induced re-expression of ERa mRNA and
protein in ER-negative human breast cancer cells
MDA-MB-231 and Hs578T cells were used as a model of ER-
negative breast cancers. These human cells are particularly
suitable for preclinical studies because they are highly aggressive
[13]. MCF-7 cells served as a positive control. RT-PCR and
western blotting analysis revealed abundant ERa mRNA and
protein in MCF-7 cells but none in MDA-MB-231 (Fig. 1A) and
Hs578T cells (Fig. 1B). Exposure of MDA-MB-231 and Hs578T
cells to arsenic trioxide for 6 days induced re-expression of ERa
mRNA and protein. The methyl donor, SAM, reduced arsenic
trioxide-induced up-regulation of ERa mRNA and protein
expression. Furthermore, we also observed the re-expression of
ERa protein in MDA-MB-231 cells (Fig. 1C) and Hs578T cells
(Fig. 1B) treated with a known demethylating agent 5-aza-dC
alone. These data are consistent with the concept that demeth-
ylation of the ERa promoter is linked to arsenic trioxide-mediated
ERa re-expression.
Arsenic trioxide induced restoration of ERa function in
ER-negative human breast cancer cells
Estrogen exerts its effects by binding to ER, which functions as
transcription factor controlling cell proliferation and differentia-
tion [14,15]. As determined by MTS assays, proliferation of ER-
positive MCF-7 cells was stimulated by exposure to E2 and
inhibited by exposure to OHT or ICI. On the other hand, none of
these treatments affected the proliferation of the ER-negative
MDA-MB-231 cells (Fig. 2A). After exposure of the cells to
2 mmol/L of arsenic trioxide, the response of MDA-MB-231 cells
to E2, OHT and ICI was restored, although the degree of growth
stimulation/inhibition was less than that of MCF-7 cells.
To evaluate further the transcriptional activity of re-expressed
ERa in ER-negative cells, the plasmid pERE-TATA-Luc+ and the
rat ERa expression vector rERa/pCI were transiently co-
transfected into ER-negative MDA-MB-231 cells as positive
controls. The plasmid phRL-tk was used as internal control for
transfection efficiency and cytotoxicity. As shown in Fig. 2B, E2
induced a 2.5-fold enhancement in luciferase activity in MDA-
MB-231 cells transfected with pERE-TATA-Luc+ and rERa/pCI
and exposed to 100 nM E2 for 24 hr (significantly different from
control, P,0.05). The ER antagonist ICI reduced E2-induced
luciferase expression. ER-negative cells transfected only with
pERE-TATA-Luc+ and exposed to E2 or ICI showed no
significant alterations. ER-negative cells exposed to 2 mmol/L of
arsenic trioxide were likewise responsive to the stimulatory effect of
E2; the effect of arsenic trioxide on ERa-regulated transactivation
was also inhibited by ICI. These results are consistent with the
observation that arsenic trioxide pretreatment of ER-negative cells
restored ERa mRNA and functional ERa protein.
To establish that the re-expressed ERa in MDA-MB-231 and
Hs578T cells is a functionally active transcription factor that
controls the expression of ER-responsive genes, the capacity of
ligand-bound ER, through interaction with estrogen-response
elements (EREs) in the DNA sequence, to activate expression of
the estrogen responsive genes, pS2 and GREB1 was determined.
In E2 exposed ER-positive MCF-7 cells, the ER-responsive genes
were expressed, whereas MDA-MB-231 (Fig. 2C) and Hs578T
(Fig. 2D) cells only showed low levels of expression of these genes.
Re-expression of ERa induced by arsenic trioxide in ER-negative
cells was associated with increased expression levels of the ER-
responsive genes, pS2 and GREB1, in the presence of E2, and
their expression was inhibited by SAM, OHT or ICI (Fig. 2C and
2D). As expected, the expression of pS2 and GREB1 were
upregulated following exposure of demethylating agent 5-aza-dC
in ER-negative cells (Fig. 2D).
Arsenic trioxide induced functional re-expression of ERa
in in vivo
Following the illustration of arsenic trioxide-induced functional
re-expression of ERa in in vitro, we further examined whether
arsenic trioxide induces functional re-expression of ERa in an
animal model. MDA-MB-231 cells were mixed with Matrigel and
injected into the flank of nude mice. Arsenic trioxide (2 mg/kg.bw)
was administered i.p. in 100 ml of sterile saline for 4 weeks. We
observed that treatment of MDA-MB-231 tumors to arsenic
trioxide resulted in significant re-expression of ERa mRNA and
protein (p=0.0093) in four out of five mice, as measured by RT-
PCR and Western blot analyses (Fig. 3A and 3B). Re-expression of
ERa protein by arsenic trioxide treatment was further demon-
strated by immunohistochemical staining (Fig. 3C). Expression of
the ER-responsive genes, pS2 and GREB1 were also induced by
arsenic trioxide in ER-negative tumors (4/5) (Fig. 3A). These in
vivo results further confirm our in vitro findings. Taken together,
these data show that arsenic trioxide significantly induces
functional re-expression of ERa in an in vivo model.
Arsenic trioxide-induced demethylation of ER promoter
CpG island
Since demethylation of ERa promoter could induce the
expression of ERa, it was still not clear whether that the re-
expression of ERa induced by arsenic trioxide is also mediated
through demethylation of the ERa promoter. This possibility was
examined, for bisulfite-treated DNA from breast cancer cells, by
nested methylation-specific PCR (n-MSP), the most sensitive
method for determining methylated states. A region of 2000 bp of
the ERa promoter and 500 bp downstream of the annotated
transcription start site (TSS) was analyzed by Methyl Primer
Express software to design MSP primers. This region was also
analyzed by the online program, MethPrimer (www.urogene.org/
methprimer), to design bisulfite sequencing PCR (BSP) primers.
The primers for BSP and MSP covered the same region, 500 bp
downstream of the annotated TSS, a region of high CpG density
and partial overlap (Fig. 4A).
n-MSP was performed by two rounds of PCR as described in
Materials and Methods. DNA bands in lanes labeled with U
indicate MSP products amplified with primers recognizing the
unmethylated promoter sequence (Fig. 4B). DNA bands in lanes
labeled with M represent amplified MSP products with methyl-
ation-specific primers. DNA from untreated MDA-MB-231 cells
yielded a PCR product only with methylation-specific primers,
whereas DNA from MCF-7 cells yielded a PCR product only with
unmethylation-specific primers. Exposure of cells to increasing
concentrations of arsenic trioxide led to decreasing levels of the
PCR product corresponding to methylated CpG islands. SAM
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ERa promoter.
To corroborate this conclusion, bisulfite genome sequencing
PCR (BSP) was performed to measure methylation status. The
status of individual CpG sites was determined by comparison with
the sequence from known ERa gene sequences. With bisulfite
modification, originally unmethylated CG changes to TG,
whereas methylated CG does not change. As shown in Fig. 5A,
in MCF-7 cells there are mostly TGs, but CGs are predominant in
MDA-MB-231 cells. This is consistent with the MSP results and
indicates that the ERa promoter is mostly unmethylated in MCF-
7 cells but mostly methylated in MDA-MB-231 cells. After cellular
exposure to 2 mmol/L of arsenic trioxide, most CGs changed to
TGs. This indicates that, in MDA-MB-231 cells, the ERa
promoter is demethylated. In the presence of SAM, some of the
TGs changed into CGs.
The region sequenced contains 28 CpG dinucleotides, indicated
by circles. CpG islands of MCF-7 were completely unmethylated.
In contrast, the ER-negative MDA-MB-231 cells were hyper-
methylated. In MDA-MB-231 cells, there was partial demethyl-
ation of CpG islands after exposure to 2 mmol/L arsenic trioxide.
The combination of arsenic trioxide and SAM partially restored
the methylation status of MDA-MB-231 cells. The values and
statistical differences are expressed in following figure (Fig. 5B).
The results confirmed that arsenic trioxide-induced demethylation
of the ERa promoter is random, not site-specific.
Arsenic trioxide altered expression of DNMTs and MBD2
proteins in MDA-MB-231 cells
In ER-negative MDA-MB-231 cells, the methylated ER
promoter is associated with DNMTs and methyl-binding proteins.
We investigated whether treatment with arsenic trioxide alters the
level of DNMTs and MBD2 protein expression. As showed in
Fig. 6A–C, the expression levels of DNMT1 and DNMT3a
protein in MDA-MB-231 cells was higher than in MCF-7 cells,
meanwhile we found that exposure of MDA-MB-231 cells to
arsenic trioxide for 6 days reduced DNMT1 and DNMT3a and
increased MBD2 protein levels; cotreatment with SAM resulted in
an opposite effect, and with increased concentration of exposure to
arsenic, there was more down-expression of DNMT1 and
DNMT3a and up-expresion of MBD2 protein. The level of
DNMT3b protein was unaltered after arsenic trioxide and/or
SAM treatments.
Arsenic trioxide altered the association of DNMT1 with
ERa promoter in MDA-MB-231 cells
We next determined the effects of arsenic trioxide on the
association of DNMT1 with the ERa promoter using ChIP assays
Figure 1. ERa mRNA and protein re-expression induced by arsenic trioxide in MDA-MB-231 cells (A) and Hs578T cells (B). ERa protein
re-expression induced by AZA (2.5 mmol/L for 4 days) in MDA-MB-231 cells (C). RT-PCR and Western blotting analysis showed the re-expression of ER
mRNA and protein after exposure of cells to arsenic trioxide (1, 2, 4 mmol/L for 6 days), whereas SAM (200 mmol/L for 6 days) reduced the degree of
re-expression. The ER-positive prototype, MCF-7, was used as a positive control; untreated ER-negative MDA-MB-231 cells were used as a negative
control. GAPDH and b-Actin provided a control for the amount of intact RNA and protein used in the reactions. ## P,0.01 compared with control
cells. # P,0.05 compared with control cells. *P,0.05 compared with cells exposed to 1 mM arsenic trioxide.
doi:10.1371/journal.pone.0035957.g001
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DNMT1 protein is associated with the silenced ERa promoter
in MDA-MB-231 breast cancer cells, whereas the active ERa
promoter in MCF-7 cells shows little association of DNMT1
protein (Figure. 6D). Treatment of MDA-MB-231 cells with
arsenic trioxide alone leads to a significant reduction in DNMT1
occupancy of the ERa promoter, and this was antagonized by co-
treatment with SAM. Thus, reduction of DNMT1 protein
expression along with partial dissociation of DNMT1 from the
ERa promoter may be responsible for the ERa reactivation in
cells exposed to arsenic trioxide.
Discussion
Estrogen and its receptor are involved in the development and
function of the mammary gland. Since the effects of endocrine
therapy are primarily mediated through ERa, its expression is a
predictor of response to treatment with selective estrogen receptor
modulators (SERMs). Lack of ERa expression is the dominant
mechanism for de novo resistance to 4-hydroxytamoxifen
[16,17,18,19]. In addition, some breast cancers that are initially
ER-positive lose ERa expression during tumor progression and
attain hormone unresponsiveness [3]. ER-negative tumors are
more aggressive and are associated with poor histological
differentiation and a higher growth fraction. New strategies for
reactivation ERa and sensitization of ER-negative tumors to
endocrine treatment are required. The mechanism for silencing
ERa in the ER-negative MDA-MB-231 cells is not clear. Although
mechanisms for the lack of ERa expression in breast cancer have
been investigated [20]; hypermethylation of the ERa promoter
represents the first identified mechanism. The present study
provides evidence that exposure of ER-negative breast cancer cells
to arsenic trioxide leads to re-expression of ERa mRNA and the
ERa protein. Nevertheless, the level of expression is lower than in
MCF-7 cells, which are ER-positive, indicating that there could be
other mechanisms involved in silencing of ERa. Other epigenetic
events, such as deacetylation and methylation of histones, are
involved in the regulation of promoter transcription. Exposure to
inhibitors of HDACs, including trichostatin A and vorinostat, lead
to re-expression of ERa in ER-negative cells such as MDA-MB-
231 [21].
Arsenic trioxide is effective in treating acute promyelocytic
leukemia, and its therapeutic effects on solid tumors are being
evaluated [9]. Arsenic trioxide could suppress cancers of the liver,
prostate, and esophagus through demethylation or, for example,
by induction of apoptosis. Zhang et al recently showed that arsenic
Figure 2. Re-expression of functional ERa in ER-negative MDA-MB-231 and Hs578T cells by arsenic trioxide. (A) Effect of arsenic
trioxide (2 mmol/L for 6 days), E2 (10 nmol/L for 24 hr), OHT (10 mmol/L for 24 hr), and ICI (2 mmol/L for 24 hr) on cell growth was determined by
MTS. MCF-7 and MDA-MB-231 cells were exposed to E2, OHT or ICI for 24 hr before assay. In addition, MDA-MB-231 cells were exposed to arsenic
trioxide (2 mmol/L for 6 days), as described, along with E2, OHT or ICI for 24 hr before MTS assay. This experiment was repeated twice with similar
results. (B) The transcriptional activities of re-expressed ERa was examined in MDA-MB-231 cells by luciferase reporter gene assay. Cells were
transiently co-transfected with 0.5 mg of pERE-TATALuc+, 0.2 mg of rERa/pCI, and 0.1 mg of phRL-tk as an positive control; untreated MDA-MB-231
cells were transiently co-transfected with 0.5 mg of pERE-TATALuc+ and 0.1 mg of phRL-tk as a negative control. MDA-MB-231 cells were exposed to
arsenic trioxide alone (2 mmol/L for 6 days), or in combination with E2 (10 nmol/L) or ICI (2 mmol/L) for 24 hr. The cell lysates were analyzed by use of
the Dual-Luciferase Reporter Assay System kit. Ethanol solvent was used as control, and transcriptional activity was presented as fold of control.
Values are presented as the means 6 SD of three independent experiments. (C) Expression of ERa and its target genes (pS2 and GREB1) in MDA-MB-
231 cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were exposed to SAM (200 mmol/L for 6 days), OHT
(10 mmol/L for 24 hr), ICI (2 mmol/L for 24 hr), or vehicle in fresh estrogen-free medium. This experiment was repeated twice with similar results. (D)
Expression of ERa target genes pS2 and GREB1) in Hs578T cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were
exposed to SAM (200 mmol/L for 6 days), AZA (2.5 mmol/L for 4 days), or vehicle in fresh estrogen-free medium. This experiment was repeated twice
with similar results.
doi:10.1371/journal.pone.0035957.g002
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inhibits tumour growth in mice [22]. However, there is evidence
that MDA-MB-435 cell line is not actually from a breast cancer
lineage, but in fact are derived from a melanoma cell line, M14
[23]. Zhang’s paper used MDA-MB-435s cell line, which is a
derivative of the parent MDA-MB-435 cell line, and therefore is
also a melanoma lineage. Thus, the possible use of arsenic trioxide
for the treatment of ER-negative breast cancer has not previously
been reported.
Arsenic trioxide, as an endocrine-disrupting chemical, act as
hormone mimetic and as either agonist or competitive antagonist
dependent on the level of endogenous estrogens. It is now
generally accepted that ER protein is targeted for rapid
degradation via the ubiquitin- proteasome pathway in response
to E2 in breast cancer cells. Stoica et al demonstrate that arsenic
trioxide mimics the effects of E2 in the ERa-positive human breast
cancer cell line MCF-7 [24]. Chow et al also found that arsenic
trioxide could down-regulate ERa mRNA and protein levels [25].
Different from Stoica’s study, Chow et al found that arsenic
trioxide abolished transcriptional induction of the estrogen
responsive gene pS2 mediated by E2. Arsenic trioxide exhibits
anti-estrogenicity on MCF-7 cells. The different results of Stoica
and Chow are likely a result of one or more differences in
experimental culture medium. Arsenic trioxide can act as an
agonist for ER [24], activating it in the absence of hormone(phe-
nol red-free IMEM supplemented with 5% charcoal stripped calf
serum). However, arsenic trioxide can act as an antagonist for ER
[25], inhibiting it in the presence of hormone (RPMI 1640
medium supplemented with 10% dextran-coated charcoal-
stripped FBS). It is well established that phenol red in culture
medium is estrogenic. In our study, the medium we used was
similar to that of Stoica’s study (phenol red–free DMEM
supplemented with 10% CS-FBS), which was estrogen-free. In
this medium, arsenic trioxide induced the re-expression of ERa
through demethylating, it also can act as an agonist for ER,
activating ER via a mechanism similar to Stoica’s study(ERa
protein degradation). Combining the effects of demethylation and
estrogenicity, arsenic trioxide induces a weak expression of ER
protein in ER-negative breast cancer cells.
ERa, a predictor of prognosis and response to endocrine
therapy, functions in development of normal breast tissue. It has
also been linked to mammary carcinogenesis, breast tumor
progression, and outcomes for breast cancer patients [26]. To
date, the molecular mechanisms underlying the loss of ERa in
breast cancer have been poorly understood. Hypermethylation of
the CpG island in the ERa promoter is known to be responsible
for silencing of ERa expression in ER-negative breast tumors [19].
In the present report, the state of CpG islands in ER-positive
breast cancer cells and ER-negative breast cancer cells was
examined by two methods, MSP and BSP. Our results
demonstrate that the CpG islands of MCF-7 were completely
unmethylated in contrast with the ER-negative MDA-MB-231
cells, which were hypermethylated, and our results demonstrate
that exposure of MDA-MB-231 cells to arsenic trioxide alone leads
to a significant reduction in the extent of CpG dinucleotide
methylation in comparison with untreated MDA-MB-231 cells.
This suggests that arsenic trioxide induces demethylation of the
ERa promoter. This compound induces apoptosis and has
growth-suppressive effects as a treatment for acute promyelocytic
leukemia and solid tumors [27,28,29,30]. But its effects on
demethylation are still few [31,32,33]. Our results confirm that
arsenic could act as a demethylation agent, and demethylation of
ERa promoter induced by arsenic trioxide is not site-specific.
Arsenic trioxide reactivates functional ERa and also induces
demethylation of the ERa promoter. Thus, we hypothesize that
arsenic trioxide reactivates ERa through demethylation of the
ERa promoter, which is silent due to hypermethylation. Since
both the metabolism of arsenic and DNA methylation require
SAM as a methyl donor [34,35], the consumption of methyl
groups in arsenic biotransformation presumably results in a
deficiency of methyl donors, reducing DNA methylation [10].
This hypothesis was evaluated by treatment of cells with the
combination of arsenic trioxide and SAM. If arsenic trioxide-
induced DNA demethylation is a consequence of lack of a methyl
donor, the effect should be reversed by SAM, as observed in this
study. The results of BSP and MSP analysis support a direct
association between ERa silencing and the hypermethylation
status of the ER promoter. Additionally, SAM reverses ERa
demethylation and the ERa re-expression induced by arsenic
trioxide. These results confirm our hypothesis that the reactivation
Figure 3. Arsenic trioxide induces functional re-expression of
ERa in vivo. (A) Expression of ERa mRNA and its target genes (pS2 and
GREB1) in MDA-MB-231 tumors. Arsenic trioxide (2 mg/kg BW) was
administered i.p. in 100 ml of sterile saline for 4 weeks. The ER-positive
prototype, MCF-7, was used as a positive control. C1–C5: control group,
A1–A5: arsenic trioxide-treated group. (B) Expression of ERa protein in
MDA-MB-231 tumors. The relative expression level of ERa protein is
represented in a scatter plot. (C) Representative immunohistochemistry
for ERa in MDA-MB-231 tumors using an anti- ERa polyclonal antibody.
doi:10.1371/journal.pone.0035957.g003
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demethylation of the ERa promoter by arsenic trioxide.
Arsenic methylation requires SAM as a cofactor and, as yet,
largely uncharacterized methyltransferases (MeTases), including
DNA MeTases (DNMTs), a group of enzymes responsible for
DNA methylation. Expression of the DNMT gene has been
definitively linked to methylation status [36,37]. Arsenic trioxide,
an inhibitor of sulfhydryl enzymes, inhibits the activity of
DNMT3a and DNMT3b, both of which contain cysteine
sulfhydryl groups [38,39]. It may function by inhibiting de novo
Figure 4. Methylation analysis of the ERa promoter by MSP in MDA-MB-231 cells. (A) A 2.5 kb genomic sequence of the ERa promoter,
analyzed by the online program, www.urogene.org/methprimer, revealed the presence of a high GC percentage CpG islands (blue) between relative
positions 2000 and 2500. Position 2000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) density was chosen
for MSP analysis. This region includes 28 CpG dinucleotides. (B), Methylation analysis of the ERa promoter by MSP in breast cancer cell lines.
Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA. At least 1% of methylated
DNA (,0.1 ng) can be detected with the ER MSP primers. In each set, M primer pairs anneal only to sequences that are methylated before bisulfite
treatment, whereas the U primer pairs anneal only to sequences that are unmethylated.
doi:10.1371/journal.pone.0035957.g004
Figure 5. Methylation analysis of the ERa promoter by BSP in breast cancer cells. (A)Shown is a representative bisulfite sequence analysis
for the high CpG region of the ERa promoter, which contains 28 CpG dinucleotides. For MDA-MB-231 and MCF-7 cell lines (10 replicates each),
methylated CpGs are designated by closed circles; unmethylated CpGs are designated by open circles. (B)Statistical chart of methylation analysis; the
results shown represent the means 6 S.E. of three independent experiments. Significant differences from the controls as determined by Student’s t
test are indicated by asterisks (P ,0.05).
doi:10.1371/journal.pone.0035957.g005
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methylation substrate such as arsenic, cells could produce greater
quantities of S-adenosylhomocysteine (SAH), the byproduct of
methylation with SAM as the methyl donor. SAH is a competitive
inhibitor of DNA methyltransferases activity [40,41]. In the
current study, expression of the DNMTs protein was measured.
The results are similar to those of reports that arsenic trioxide
inhibits DNMT1 protein in human liver and colon cancer cells
[42,43], we found that arsenic trioxide also inhibits DNMT3a
protein in ER-negative breast cancer cells. These results confirm
that arsenic trioxide metabolism consumes the methyl donor,
SAM, and inhibits DNMTs. Thus, factors involving arsenic
metabolism contribute to the level of DNA methylation in arsenic-
induced demethylation of the ERa promoter. In addition, ChIP
assays validated that DNMT1 was associated with ERa promoter
in MDA-MB-231 but not MCF-7 cells, treatment of MDA-MB-
231 cells with arsenic trioxide alone leads to a significant reduction
in DNMT1 occupancy of the ERa promoter, the partial
dissociation of DNMT1 from ERa promoter was benefit for
reactivation of silented ERa promoter. It was also antagonistic by
cotreatment with SAM. Thus, arsenic trioxide inhibition of total
DNMT1 protein along with partial dissociation of DNMT1 from
the ERa promoter facilitates ERa promoter demethylation and
reactivation.
In summary, our results identify a mechanism for ERa
reactivation by arsenic trioxide, which, through competition with
SAM for methylation of DNA and inhibition of DNMT1 protein
along with partial dissociation of DNMT1 from the ERa
promoter, causes demethylation of the ERa promoter in ER-
negative breast cancer cells. Furthermore, restoration of ERa
expression by arsenic trioxide is sufficient to induce anti-estrogen
responses in ER-negative breast cancer cells and animal model. A
better understanding of the regulatory mechanisms governing ER
gene silencing will contribute to the design of combined therapies
and to innovative strategies for drug delivery.
Figure 6. Methylation-related proteins mediate arsenic trioxide-induced re-expression of ERa. (A) Immunoblot analysis of DNMTs and
MBD2 protein. Equal amounts of protein (80 mg) from whole-cell lysates of the control MCF-7 and MDA-MB-231 cells, treated as in Fig. 1, were
separated by SDS-PAGE and subjected to Western blot analysis with specific antibodies against DNMT1, DNMT3a, DNMT3b and MBD2. Equivalence of
protein loading was demonstrated by immunoblotting with anti-GAPDH antibody. (B) Relative protein levels (mean6 SD) of DNMTs (n=3). (C)
Relative protein levels (mean6 SD) of MBD2 (n=3). (D) ChIP analysis of association of DNMT1 and ERa promoter. Cross-linked chromatin prepared
from ER-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells was immunoprecipitated with antibodies DNMT1. MDA-MB-231
cells treated as in Fig. 1. The immunoprecipitates were subjected to PCR analysis. Aliquots of chromatin taken before immunoprecipitation were used
as input controls (n=3). # P,0.05 compared with control cells. *P,0.05 compared with cells exposed to 1mM arsenic trioxide.
doi:10.1371/journal.pone.0035957.g006
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